Characterization of the maturation of human pro-apolipoprotein A-I in an in vitro model.
The reaction conditions and the protein structural features involved in the maturation of pro-apolipoprotein A-I (cleavage of pro-peptide) were investigated in an in vitro model. ProapoA-I, mutants and wild type, were expressed in the PGEX/E. coli expression system as fusion proteins with glutathione S-transferase (GST). Use of GST-proapoA-I and truncated forms of proapoA-I enabled quantitation of the amount of GST and apoA-I formed as a result of cleavage following incubation with human serum. Deletion of the pro-peptide (GST-apoA-I) resulted in complete inhibition of the reaction. Truncation of proapoA-I to residues 222, 150, 135, and 25 as well as substitution of residues -6, -5, and -4 with alanine did not affect the reaction. Substitution of residues -1, -2, 1, 3, and 4 with alanine either completely blocked or substantially inhibited cleavage of the pro-peptide. The reaction was inhibited by addition of EDTA, o-phenanthroline, dithiothreitol, and beta-mercaptoethanol and to a lesser extent by p-chloromercuriphenylsulfonic acid, but not by leupeptin, N-ethylmaleimide, PMSF, pepstatin A, or trans-epoxysuccinyl-L-leucylamido(4-guanidino)butane. Calcium was essential for the activation of the cleavage enzyme, but it had a biphasic effect on the cleavage, activating it at concentrations below 1.5 mM and inhibiting at concentrations above 1.75 mM. Manganese alone was not essential for activation of the enzyme nor did it modify the effect of low concentration of calcium. However, a high concentration of manganese partially reverted the inhibitory effect of a high calcium concentration. Thus, residues within -2 to +4 are involved in forming the cleavage site for the maturation enzyme. The reaction of maturation is inhibited by metalloprotease inhibitors and is dependent upon calcium.
Baker Medical Research Institute, Melbourne, Victoria, 3008, Australia.
L E
LE
Pyle
D
D
Sviridov
N H
NH
Fidge
D016632:Apolipoprotein A-I; D001054:Apolipoproteins A / Q000037:antagonists & inhibitors / Q000097:blood / Q000235:genetics / Q000378:metabolism*; D002118:Calcium / Q000502:physiology; D002413:Cations, Divalent / Q000494:pharmacology; D004229:Dithiothreitol / Q000494:pharmacology; D004492:Edetic Acid / Q000494:pharmacology; D004926:Escherichia coli / Q000235:genetics; D005982:Glutathione Transferase / Q000235:genetics / Q000378:metabolism; D006801:Humans; D006868:Hydrolysis; D008075:Lipoproteins, HDL / Q000378:metabolism*; D008345:Manganese / Q000502:physiology; D008623:Mercaptoethanol / Q000494:pharmacology; D010446:Peptide Fragments / Q000037:antagonists & inhibitors / Q000097:blood / Q000235:genetics / Q000378:metabolism; D010618:Phenanthrolines / Q000494:pharmacology; D010957:Plasmids / Q000096:biosynthesis / Q000097:blood / Q000138:chemical synthesis / Q000378:metabolism*; D011480:Protease Inhibitors / Q000494:pharmacology; D011498:Protein Precursors / Q000037:antagonists & inhibitors / Q000097:blood / Q000235:genetics / Q000378:metabolism*; D011993:Recombinant Fusion Proteins / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000097:blood / Q000378:metabolism
D016632:Apolipoprotein A-I; D001054:Apolipoproteins A; D002413:Cations, Divalent; D008075:Lipoproteins, HDL; D010446:Peptide Fragments; D010618:Phenanthrolines; D011480:Protease Inhibitors; D011498:Protein Precursors; D011993:Recombinant Fusion Proteins; D008345:Manganese; D008623:Mercaptoethanol; D004492:Edetic Acid; D005982:Glutathione Transferase; D002118:Calcium; D004229:Dithiothreitol; C025205:1,10-phenanthroline